Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Famed COVID-19 vaccine maker Moderna Inc (NASDAQ:MRNA) has decided to pause its plans to construct a vaccine manufacturing...
Shares of Moderna (NASDAQ: MRNA) rose 6.2% on Apr 9 after management announced encouraging data from a portion of an early-stage study on mRNA-4157...
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: JNJ) a...
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said...
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during T...
A Delaware District Court sided with Arbutus Biopharma Corporation (NASDAQ:ABUS) and Genevant Sciences in their ongoing patent infringement cas...
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for ...
On Tuesday, Cathie Wood’s Ark Invest made a significant move by increasing its stake in Moderna Inc. (NASDAQ:MRNA), a leading COVID-19 vaccin...
Tuesday, Moderna Inc (NASDAQ:MRNA) said that mRNA-1283, the company’s next-generation COVID-19 vaccine, has met the primary en...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...